Abnormal glucagon response to arginine and its normalization in obese hyperinsulinaemic patients with glucose intolerance: importance of insulin action on pancreatic Alpha cells

[1]  E. Samols,et al.  Islet somatostatin--microvascular, paracrine, and pulsatile regulation. , 1990, Metabolism: clinical and experimental.

[2]  A J Scheen,et al.  Effects of pulsatile delivery of insulin and glucagon in humans. , 1989, The American journal of physiology.

[3]  E. Samols,et al.  Intra-islet regulation. , 1988, The American journal of medicine.

[4]  G. Paolisso,et al.  Pulsatile insulin delivery is more efficient than continuous infusion in modulating islet cell function in normal subjects and patients with type 1 diabetes. , 1988, The Journal of clinical endocrinology and metabolism.

[5]  Y. Yamasaki,et al.  The mechanism of exaggerated glucagon response to arginine in diabetes mellitus. , 1985, Diabetes research and clinical practice.

[6]  V. Rogiers,et al.  Pancreatic hormone receptors on islet cells. , 1985, Endocrinology.

[7]  L. Orci,et al.  Insulin within islets is a physiologic glucagon release inhibitor. , 1984, The Journal of clinical investigation.

[8]  L. Orci,et al.  Quantitative electron microscopic autoradiography of insulin, glucagon, and somatostatin binding sites on islets. , 1982, Science.

[9]  J. Tobin,et al.  Feedback inhibition of insulin secretion by insulin: relation to the hyperinsulinemia of obesity. , 1982, The New England journal of medicine.

[10]  J. Palmer,et al.  In vivo inhibition of glucagon secretion by paracrine beta cell activity in man. , 1981, The Journal of clinical investigation.

[11]  Y. Yamasaki,et al.  Perfect Normalization of Excessive Glucagon Responses to Intravenous Arginine in Human Diabetes Mellitus With the Artificial Beta-Cell , 1980, Diabetes.

[12]  R. DeFronzo,et al.  Glucose clamp technique: a method for quantifying insulin secretion and resistance. , 1979, The American journal of physiology.

[13]  R. Kawamori,et al.  The development of an artificial beta cell system and its validation in depancreatized dogs: the physiological restoration of blood glucose homeostasis. , 1979, Medical progress through technology.

[14]  P. Lefèbvre,et al.  Glucagon and diabetes: A reappraisal , 1979, Diabetologia.

[15]  R. Kawamori,et al.  Normalization of the Paradoxic Secretion of Glucagon in Diabetics Who Were Controlled by the Artificial Beta Cell , 1979, Diabetes.

[16]  Y. Yamasaki,et al.  Importance of insulin secretion based on the rate of change in blood glucose concentration in glucose tolerance, assessed by the artificial beta cell. , 1978, Acta endocrinologica.

[17]  W. Clarke,et al.  Glucagon, insulin and glucose response to physiologic testing in normal and massively obese adults. , 1977, Metabolism: clinical and experimental.

[18]  G. Weir,et al.  Glucagon secretion from the perfused rat pancreas following acute and chronic streptozotocin. , 1976, Metabolism: clinical and experimental.

[19]  E. Samols,et al.  Remarkable potency of somatostatin as a glucagon suppressant. , 1976, Metabolism: clinical and experimental.

[20]  P. Raskin,et al.  Effect of Insulin on the Exaggerated Glucagon Response to Arginine Stimulation in Diabetes Mellitus , 1976, Diabetes.

[21]  R P Eaton,et al.  Role of Insulin and Glucagon in Obesity , 1974, Diabetes.

[22]  M. L. Matute,et al.  Plasma glucagon in obesity. Response to arginine, glucose and protein administration. , 1973, The New England journal of medicine.

[23]  L. Stimmler.  Immunoassay of insulin with insulin antibody precipitate. , 1963, Lancet.

[24]  R. Unger,et al.  Relationship of glucagon suppression by insulin and somatostatin to the ambient glucose concentration. , 1987, The Journal of clinical investigation.

[25]  西野 友善.  Glucagon radioimmunoassay with use of antiserum to glucagon C-terminal fragment , 1987 .